Skip to content
OpenCapital
Get started

Alnylam Pharmaceuticals ALNY Operating Income

Operating Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$117.42M+20.0%
Arrowhead Research logo
Arrowhead ResearchARWR
-$141.26M-137%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$11.37M-14.4%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$168.91M+757%
Wave Life Sciences logo
Wave Life SciencesWVE
-$31.3M+37.2%

Other financials

Income statement

See full
Revenue$1.2B+96.4%
Gross profit$959.7M+83.1%
Net income$206.0M+1,229%
EPS (diluted)$1.51+1,179%

Balance sheet

See full
Cash & equivalents$1.7B+67.5%
Total debt$263.7M-4.5%
Total equity$1.1B+152%
Total assets$5.1B+21.7%

Cash flow

See full
Operating cash flow$70.5M+159%
CapEx$21.8M+143%
Free cash flow$48.7M+138%

Valuation

See full
Market cap$40.19B+0.6%
Enterprise value$38.74B-0.8%
P/E80×—
P/S9.4×-6.8×

Profitability

See full
Gross margin81%-5.3pp
Operating margin17.5%+14.4pp
Net margin11.7%+8.0pp
FCF margin15%+12.7pp

Returns & leverage

See full
Return on equity66.9%—
Debt / equity0.2×-0.4×
Current ratio3.1×+0.1×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Alnylam Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alnylam Pharmaceuticals's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alnylam Pharmaceuticals's operating income?
Alnylam Pharmaceuticals (ALNY) reported operating income of $268.64M in Q1 2026.
How has Alnylam Pharmaceuticals's operating income changed year-over-year?
Alnylam Pharmaceuticals's operating income increased by 1386.1% year-over-year, from $18.08M to $268.64M.
What is the long-term trend for Alnylam Pharmaceuticals's operating income?
Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's operating income has grown at a -8.3% compound annual growth rate (CAGR), from -$708.65M to $501.58M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.